HPIVs Antigen Rapid Test – EZER™ Antigen Assay

What is in the HPIVs Antigen Rapid Test?

Each kit contains:

• 20 EZER™ HPIVs Antigen Rapid Test devices

• 20 sterile nasopharyngeal swabs

• 20 extraction tubes prefilled with extraction buffer

• 20 dropper nozzles

• 1 tube stand

• 1 package insert with instructions for use

The test detects Human Parainfluenza Virus antigens through immunochromatographic analysis. When HPIV antigen is present, a red line appears in the corresponding test region (T1, T2, and/or T3) along with the control (C) line, confirming a valid result.

Role of Human Parainfluenza Virus in Disease

Human Parainfluenza Viruses are a common cause of acute respiratory tract infections, particularly in infants, young children, the elderly, and immunocompromised individuals. HPIV-1, HPIV-2, and HPIV-3 are associated with illnesses such as croup, bronchiolitis, pneumonia, and upper respiratory infections.

Because early symptoms often overlap with other viral respiratory diseases, rapid antigen detection plays a critical role in:

• Early differentiation of respiratory pathogens

• Timely clinical decision-making

• Infection control and cohorting

• Reducing unnecessary antibiotic use

HPIV antigens are most reliably detected during the early phase of infection, making rapid testing especially valuable shortly after symptom onset.

About the EZER™ HPIVs Antigen Rapid Test

The EZER™ HPIVs Antigen Rapid Test is developed by Genesis Biotech and uses monoclonal antibodies specific to the nucleoproteins of HPIV types 1, 2, and 3. The assay incorporates color microsphere–labeled antibodies to enable clear visual interpretation.

Performance summary:

• Sensitivity:

  • HPIV-1: 91.3%

  • HPIV-2: 95.0%

  • HPIV-3: 89.7%

• Specificity: 100% for all three types

• Overall agreement: up to 98.1%

• Time to result: 15 minutes

No cross-reactivity was observed with common respiratory viruses such as Influenza A/B, RSV, Adenovirus, Rhinovirus, Human Coronaviruses, or bacterial respiratory pathogens.

The test is validated against cell culture methods and is suitable for routine clinical use.

Principle and Workflow

Sample types:

• Nasopharyngeal swabs

• Nasal aspirates

Test procedure:

1. Allow test device and samples to reach room temperature

2. Extract the sample using the provided extraction buffer

3. Add 3 drops of extracted sample to the test cassette

4. Read results at 15 minutes (do not interpret after 30 minutes)

Result interpretation:

• Positive: Control line (C) + one or more test lines (T1, T2, T3)

• Negative: Control line (C) only

• Invalid: No control line

The simple workflow and visual readout make the test suitable for both laboratory and point-of-care environments.

Clinical Application

The EZER™ HPIVs Antigen Rapid Test is intended for:

• Diagnosis of acute respiratory infections

• Pediatric and hospital respiratory screening

• Emergency department testing

• Infection control and outbreak management

• Point-of-care use in decentralized healthcare settings

By enabling rapid identification of HPIV infections, the test supports early clinical decisions, appropriate patient isolation, and improved respiratory disease management.